Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 1817080 placebo-controlled phase 2 study in overactive bladder with urgency urinary incontinence
2019-002575-34Phase 2Completed
- Sponsor
- Bayer
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eliapixant in overactive bladder (OAB), sponsored by Bayer. Started Feb 2020; status: completed.
02
Drugs
eliapixant
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2019-002575-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002575-34.